Neurophoenix‘s strategic committee consists of the leadership team, a representative of the Institut Pasteur and two independent members. Its mission is to support and advise the management of the Company.
François Romaneix has been Senior Executive Vice-President Administration and Finance of Institut Pasteur since April 2017. A graduate of ENA and Sciences Po Paris, he holds a master’s degree in economics and has extensive experience of ministerial offices and public health issues.
General Inspector of Social Affairs, he served, from May 2002 to September 2005, as Director of the Asbestos Victims’ Compensation Fund and then as Director of the French National Authority for Health (HAS) until September 2011.
Before joining the Institut Pasteur, François Romaneix was Director of the Private Office of Annick Girardin, Minister for the Civil Service.
Philippe Grand, independent member, is a Partner at EY Advisory and responsible for the Innovation activity. He is involved in support missions for innovative companies (fundraising, roadmap, collaborative research, etc.), evaluation of public policies and actions supporting innovation or the promotion of research.
Philippe has carried out more than 500 support missions to the creation of technological companies, particularly for the negotiation of alliances, technology transfer, fundraising assistance, the validation of the launch strategy, and the financial and legal engineering related to the creation of activities in different sectors and in particular the biotech sector.
Franck Mouthon, independent member, is a graduate of the Ecole Normale Supérieure (Ulm), and co-founder and CEO of Theranexus. He is also Chairman of France Biotech since September 2019. Before founding Theranexus, he supervised a CEA research team and various interdisciplinary projects on neurodegenerative diseases.
In 2013, he founded Theranexus from a technology identified at the CEA on the simultaneous targeting of neurons and non-neuronal cells of the brain (glial cells) to improve the management of neurological diseases, and of which he negotiated the exclusive and global license. Theranexus is a clinical stage biopharmaceutical company listed on Euronext Growth (ALTHX).
Tom Shepherd, independent member, has more than 30 years of experience leading and developing biotech companies in France and internationally (United States, United Kingdom, Switzerland, Australia and South Korea) with in-depth skills in the formulation and execution of business strategy, the development of therapeutic products and technologies, accessing capital, business development, license negotiation, mergers and acquisitions. Tom is currently CEO of Captor Therapeutics.
He holds a PhD in Biochemistry from the University of Strathclyde in Scotland and a Continuing Executive Program from the London Business School.